Page 43 - Biomarkers for risk stratification and guidance in heart failure

Chapter 2
Appendix 1. Assay performance characteristics
Marker
NT-proBNPa Hs-cTnTb Hs-CRPc Cystatin-Cd Galectin-3e
LOD
5.1 μg/L* 0.001 μg/L 0.175 mg/L** 0.004 mg/L 20 1.13 μg/L 19
Interassay CV
6.8% at 74.4 μg/L* 3.0% at 0.021 μg/L,
1.4% at 3.03 μg/L 3.7% at 0.25,
1.0% at 45 mg/L**
2.0% at 0.9 mg/L, 2.2% at 1.8 mg/L 10
10% at 6 μg/L, 7% at 21 μg/L, 15% at 70 μg/L 19
Reference value
99%: males 265 μg/L, females 301 μg/L 16
99%: 0.016 μg/L 95%: 8.4 mg/L 17 95%: 0.95 mg/L* 95%: 20.3 μg/L 19
a: measured by the electrochemiluminescence immunoassay using an Elecsys 2010 analyser (Roche Diagnostics GmbH, Mannheim, Germany). b: measured by precommercial highly sensitive fifth generation cTnT assay (hs-cTnT) using an the Elecsys 2010 analyser (Roche Diagnostics GmbH, Mannheim,Germany). c: measured by the CardioPhase hs-CRP assay on the BN ProSpec (Siemens Healthcare Diagnostics Inc. New York, United States) d: measured by the N Latex Cystatin C assay on the BN ProSpec (Siemens Healthcare Diagnostics Inc. New York, United States). e: measured by the Galectin-3 electro-chemiluminescence immunoassay (BG Medicine Inc., Waltham, MA, USA United States) on the iMarkTM Microplate Absorbance Reader (Bio-Rad Laboratories, Inc). * provided by manufacturer ** validated in our laboratory. LOD=limit of detection; CV=coefficient of variability.
Appendix 2. Correlations between biomarkers
NT-proBNP Hs-cTnT Hs-CRP Cystatin-C Galectin-3
* P<0.001
NT-proBNP Hs-cTnT
- - 0.55* - 0.29* 0.29* 0.46* 0.46* 0.45* 0.45*
Hs-CRP Cystatin-C Galectin-3
- - - - - - - - - 0.19* - - 0.32* 0.70* -
42